Fabrizio Facchinetti
- Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patientsBy Simon Lea, Aleksandra Metryka, Fabrizio Facchinetti and Dave SinghSimon Lea1Medicines Evaluation Unit, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, United KingdomAleksandra Metryka1Medicines Evaluation Unit, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, United KingdomFabrizio Facchinetti2Department of Pharmacology, Chiesi Pharmaceuticals, Parma, ItalyDave Singh1Medicines Evaluation Unit, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, United Kingdom
- Pharmacological inhibition of epidermal growth factor receptor modulates cigarette smoke-induced CXCL8 release but not VEGF releaseBy Giorgia Volpi, Nadia Moretto, Riccardo Patacchini and Fabrizio FacchinettiGiorgia Volpi1Department of Pharmacology, Chiesi Farmaceutici S.p.a., Parma, ItalyNadia Moretto1Department of Pharmacology, Chiesi Farmaceutici S.p.a., Parma, ItalyRiccardo Patacchini1Department of Pharmacology, Chiesi Farmaceutici S.p.a., Parma, ItalyFabrizio Facchinetti1Department of Pharmacology, Chiesi Farmaceutici S.p.a., Parma, Italy
- Cigarette smoke upregulates IL-8/CXCL8 expression by augmenting mRNA stability via p38 MAPK/MK2 signalling in normal human pulmonary cellsBy Nadia Moretto, Giorgia Volpi, Manminder Kaur, Claudia Iadicicco, Serena Bertolini, Gessica Marchini, Dave Singh and Fabrizio FacchinettiNadia Moretto1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, ItalyGiorgia Volpi1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, ItalyManminder Kaur2Manchester Academic Health Science Centre, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, Manchester, United KingdomClaudia Iadicicco1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, ItalySerena Bertolini1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, ItalyGessica Marchini1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, ItalyDave Singh2Manchester Academic Health Science Centre, NIHR Translational Research Facility, University Hospital of South Manchester Foundation Trust, Manchester, United KingdomFabrizio Facchinetti1Department of Pharmacology and Toxicology, Chiesi Farmaceutici S.p.A., Parma, Italy
- Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokinesBy Michael Edwards, Fabrizio Facchinetti, Maurizio Civelli, Gino Villetti and Sebastian JohnstonMichael Edwards1Airway Disease Infection Section, MRC Centre for Allergic Mechanisms of Asthma, Imperial College London, London, United KingdomFabrizio Facchinetti2Corporate Pre-Clinical R&D, Chiesi Farmaceutici, Parma, ItalyMaurizio Civelli2Corporate Pre-Clinical R&D, Chiesi Farmaceutici, Parma, ItalyGino Villetti2Corporate Pre-Clinical R&D, Chiesi Farmaceutici, Parma, ItalySebastian Johnston1Airway Disease Infection Section, MRC Centre for Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom
- In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic windowBy Gino Villetti, Pier Tonino Bolzoni, Franco Bassani, Marco Bergamaschi, Paola Lorenza Caruso, Loredana Battipaglia, Angelo Sala, Fabrizio Facchinetti, Chiara Carnini and Maurizio CivelliGino Villetti1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyPier Tonino Bolzoni1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyFranco Bassani1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyMarco Bergamaschi1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyPaola Lorenza Caruso1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyLoredana Battipaglia1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyAngelo Sala2Department of Pharmacological Sciences, University of Milan, Milan, ItalyFabrizio Facchinetti1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyChiara Carnini1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, ItalyMaurizio Civelli1Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.a., Parma, Italy
- In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profileBy Fabrizio Facchinetti, Nadia Moretto, Paola Caruso, Gessica Marchini, Raffaella Bosco, Chiesa Carnini, Maurizio Civelli and Gino VillettiFabrizio Facchinetti1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyNadia Moretto1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyPaola Caruso1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyGessica Marchini1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyRaffaella Bosco1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyChiesa Carnini1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyMaurizio Civelli1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyGino Villetti1Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy
- Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissueBy Simon Lea, Aleksandra Metryka, Fabrizio Facchinetti, Maurizio Civelli, Gino Villetti and Dave SinghSimon Lea1Inflammation and Repair, University of Manchester, Manchester, United KingdomAleksandra Metryka1Inflammation and Repair, University of Manchester, Manchester, United KingdomFabrizio Facchinetti2Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyMaurizio Civelli2Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyGino Villetti2Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, ItalyDave Singh1Inflammation and Repair, University of Manchester, Manchester, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.